Results 31 to 40 of about 1,426 (171)

Treating Thyroid Associated Ophthalmopathy in Pediatric Patients

Frontiers in Endocrinology, 2022
Thyroid associated ophthalmopathy (TAO) is a common extra-thyroid clinical manifestation of Graves’ disease. It is an inflammatory disease of the eye and orbital tissues.
Tianyu Dong, Zhujun Fu, Xu Wang
doaj   +1 more source

Supplementary Material for: Oral corticosteroids for teprotumumab-related hearing loss: a case report

, 2023
Teprotumumab is a novel IGF-1R inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation.
Lu T.J. (14801866), Amarikwa L. (14801869), Kossler A.L. (14801881), Inserra M. (14801875), Dosiou C. (14801878), Winn B.J. (14801872)   +5 more
core   +1 more source

Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study

American Journal of Ophthalmology Case Reports, 2021
Purpose: To study post-interventional findings in patients with dysthyroid optic neuropathy (DON) treated with teprotumumab. Observations: In this multicenter observational Case series, patients with DON were treated with teprotumumab, an insulin-like ...
Connie M. Sears, Yao Wang, Lucy A. Bailey, Roger Turbin, Prem S. Subramanian, Raymond Douglas, Kimberly Cockerham, Andrea L. Kossler   +7 more
doaj   +1 more source

Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform

, 2023
Clinical and Translational Medicine, Volume 13, Issue 4, April 2023.
Jing Hu, Jiali Wu, Qihuang Jin, Ling Zhang, Ning Shen, Yiyang Shu, Lu Cheng, Jian Zhang, Guangyi Hu, Kangjia Lv, Qizhi Jian, Hui Chen, Fang Zhang, Xiaodong Sun   +13 more
wiley   +1 more source

Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease

, 2022
Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non ...
Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas
core   +2 more sources

Teprotumumab Treats Sight-Threatening Thyroid Eye Disease

, 2021
We report a unique case of dysthyroid optic neuropathy (DON) treated primarily with teprotumumab and corticosteroids. The patient showed rapid improvement in visual acuity, visual field loss, color vision, and reduction in exophthalmos.
Michael Lopez Lopez; Dilip Thomas; Ciera Thomas
core  

Teprotumumab for Thyroid Eye Disease-related Strabismus [PDF]

PURPOSE: To assess and quantify teprotumumab's effect on thyroid eye disease-related strabismus by change in measured horizontal and vertical deviations and change in extraocular motility.
Dallalzadeh, Liane O, Rootman, Daniel B, Robbins, Shira L, Chen, Lillian, Khitri, Monica R, Velez, Federico G, Villatoro, George A, Demer, Joseph L, Movaghar, Mansoor, Karlin, Justin N, Kikkawa, Don O, Sim, Myung S, Korn, Bobby S, Granet, David B   +13 more
core   +1 more source

Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease

Case Reports in Ophthalmology
Introduction: Thyroid eye disease (TED) is a rare condition involving autoimmune-mediated inflammation of the orbit and periocular structures, which can result in many debilitating symptoms.
Savannah Cottom, Brayden Barrientez, Andrew Melson   +2 more
doaj   +1 more source

Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators

, 2021
Thyroid eye disease (TED) is a vision-threatening and debilitating condition that until very recently had no Food and Drug Administration (FDA)-approved medical therapies. Teprotumumab has recently been approved to treat TED.
Fleming, James, Raymond S. Douglas, Rosa A. Tang, Brian Fowler, Dailey, Roger A, Yao Wang, Tang, Rosa A, Wang, Yao, Roger A. Dailey, Douglas, Raymond S, Sara T. Wester, James Fleming, Gerald J. Harris, Jade S. Schiffman, Wester, Sara T, Harris, Gerald J, Terry J. Smith, Fowler, Brian, Schiffman, Jade S, Smith, Terry J   +19 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source